Celularity Inc (CELU) - Total Liabilities
Based on the latest financial reports, Celularity Inc (CELU) has total liabilities worth $134.33 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore CELU net assets growth trend to track the company's year-over-year net asset growth rate.
Celularity Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Celularity Inc's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Celularity Inc to measure how efficiently the company converts operating cash flow to free cash.
Celularity Inc Competitors by Total Liabilities
The table below lists competitors of Celularity Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
LQR House Inc
NASDAQ:YHC
|
USA | $1.55 Million |
|
Wilton Resources Inc
V:WIL
|
Canada | CA$668.49K |
|
RHYTHM Biosciences Ltd
AU:RHY
|
Australia | AU$955.41K |
|
Teck Guan Perdana Bhd
KLSE:7439
|
Malaysia | RM65.58 Million |
|
Oxford Instruments PLC
LSE:OXIG
|
UK | GBX211.90 Million |
|
Sanginita Chemicals Limited
NSE:SANGINITA
|
India | Rs301.74 Million |
|
ZICOM Group Ltd
AU:ZGL
|
Australia | AU$92.26 Million |
|
OHEIM INT Co.Ltd
KQ:309930
|
Korea | ₩35.43 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Celularity Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Celularity Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -6.69 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Celularity Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Celularity Inc (2018–2024)
The table below shows the annual total liabilities of Celularity Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $123.84 Million | +20.32% |
| 2023-12-31 | $102.93 Million | -49.09% |
| 2022-12-31 | $202.16 Million | -35.76% |
| 2021-12-31 | $314.71 Million | -23.67% |
| 2020-12-31 | $412.30 Million | +7.47% |
| 2019-12-31 | $383.63 Million | +254712.53% |
| 2018-12-31 | $150.56K | -- |
About Celularity Inc
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioB… Read more